

AZUR PHARMA

September 10, 2004

Dear Doctor:

You may recognize my name – Gil Honigfeld – formerly Clinical Research Director for clozapine at Sandoz Pharmaceuticals Corporation. My first letter is designed to let you and a select group of your colleagues know about a new development concerning clozapine. Alamo Pharmaceuticals, with whom I am now affiliated, is about to introduce FazaClo™ (clozapine USP) Orally Disintegrating Tablets, clozapine in a brand-new form. These tablets, designed for discreet use without water, should help reduce medication stigma in a vulnerable target population. Our own drug registration data show that over 80% of patients studied preferred FazaClo to standard oral clozapine tablets (data on file: US New Drug Application). FazaClo is a brand product, with no possibility of substitution by other clozapine products. Your patients will receive FazaClo with every refill.


FazaClo Orally Disintegrating Tablets are indicated for the management of severely ill patients who fail to respond adequately to other medicines for schizophrenia, or who may be intolerant to their adverse effects. Bioequivalence data in patients show that FazaClo and Clozaril® tablets produce overlapping blood level curves. These new FazaClo tablets are scored and are available in 25 mg and 100 mg strengths. The tablets have a pleasant, mint taste, and disintegrate in the mouth within 15-30 seconds. Because no liquids are required, patients should find them convenient and discreet to use.

Alamo representatives are now available with placebo demonstrations of the new tablet. You will probably want to try this new placebo dosage delivery form yourself; when you do, I think you will like the mint flavor and oral disintegration method, and what FazaClo might offer to your patients.

Full prescribing information for FazaClo is enclosed, including boxed warnings regarding agranulocytosis, seizures, myocarditis, and cardio-respiratory events. More information may be found on the website www.fazaclo.com. If you'd like to speak with me directly, please call at your convenience – the number is 973 538 7100.

Thanks. I'll be in touch again.

Sincerely,



Gilbert Honigfeld, Ph.D.
Vice President, Scientific Affairs

encl: FazaClo Package insert

CT01

*Clozaril® (clozapine) is the registered trademark of Novartis® Pharmaceuticals Corporation